Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sangamo Therapeutics
(NQ:
SGMO
)
1.880
+0.180 (+10.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sangamo Therapeutics
< Previous
1
2
3
4
5
6
7
Next >
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients
August 30, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics's Return On Capital Employed Insights
August 22, 2022
According to data from Benzinga Pro, during Q2, Sangamo Therapeutics's (NASDAQ:SGMO) reported sales totaled $29.38 million. Despite a 1.83% increase in earnings, the company posted a loss of $43.17...
Via
Benzinga
Recap: Sangamo Therapeutics Q2 Earnings
August 04, 2022
Sangamo Therapeutics (NASDAQ:SGMO) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
August 04, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
April 26, 2022
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Via
Benzinga
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast
July 28, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation
July 21, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
July 19, 2022
Gainers Talis Biomedical (NASDAQ:TLIS) shares moved upwards by 10.6% to $0.94 during Tuesday's after-market session. The company's market cap stands at $25.0 million.
Via
Benzinga
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
June 01, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Wednesday
May 25, 2022
On Wednesday, 215 companies set new 52-week lows.
Via
Benzinga
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
May 05, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Sangamo Therapeutics's Earnings: A Preview
May 04, 2022
Sangamo Therapeutics (NASDAQ:SGMO) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 02, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
April 28, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
April 21, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Thursday
April 21, 2022
On Thursday, 236 companies hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
April 19, 2022
On Tuesday, 242 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was...
Via
Benzinga
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
March 29, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
March 15, 2022
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by...
Via
Benzinga
Sangamo Therapeutics: Q4 Earnings Insights
February 24, 2022
Sangamo Therapeutics (NASDAQ:SGMO) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
February 24, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
February 17, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
February 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Sangamo Therapeutics Shares Updated Interim Data From Fabry Disease Gene Therapy Trial
February 08, 2022
Sangamo Therapeutics Inc (NASDAQ: SGMO)
Via
Benzinga
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
February 07, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
January 14, 2022
During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to...
Via
Benzinga
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
January 06, 2022
From
Sangamo Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.